Welcome to our dedicated page for Sera Prognostics news (Ticker: SERA), a resource for investors and traders seeking the latest updates and insights on Sera Prognostics stock.
Sera Prognostics, Inc. reports developments in women's health diagnostics, with news centered on its PreTRM® Test for spontaneous preterm birth risk prediction in asymptomatic singleton pregnancies. The company uses proteomics, bioinformatics and pregnancy biomarker information to support maternal and neonatal health.
Recurring updates include financial results, commercial adoption and payer engagement for PreTRM, clinical evidence from the PRIME study and related publications, investor presentations, healthcare conference activity, capital allocation and financing actions supporting commercialization.
Sera Prognostics Inc., known as The Pregnancy Company®, has priced its initial public offering at $16.00 per share, offering 4,687,500 shares and expecting gross proceeds of approximately $75.0 million. Shares will begin trading on the Nasdaq under the symbol 'SERA' starting July 15, 2021, with the offering set to close on July 19, 2021, pending customary conditions. The company focuses on enhancing maternal and neonatal health through innovative pregnancy biomarkers, and has a pipeline dedicated to predicting preterm birth risks.